Vestal Point Capital LP Acquires New Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Vestal Point Capital LP acquired a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 990,000 shares of the company’s stock, valued at approximately $13,761,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new position in Tyra Biosciences in the 4th quarter valued at about $253,000. Two Sigma Advisers LP purchased a new stake in Tyra Biosciences in the fourth quarter valued at approximately $171,000. Two Sigma Investments LP lifted its stake in Tyra Biosciences by 18.1% in the fourth quarter. Two Sigma Investments LP now owns 46,269 shares of the company’s stock valued at $643,000 after buying an additional 7,093 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Tyra Biosciences during the fourth quarter worth approximately $178,000. Finally, Polar Asset Management Partners Inc. raised its stake in shares of Tyra Biosciences by 26.1% during the fourth quarter. Polar Asset Management Partners Inc. now owns 111,107 shares of the company’s stock worth $1,544,000 after purchasing an additional 23,007 shares during the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Performance

Tyra Biosciences stock opened at $9.99 on Monday. The firm has a market capitalization of $530.37 million, a price-to-earnings ratio of -6.20 and a beta of 1.17. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The stock’s fifty day moving average is $9.55 and its two-hundred day moving average is $12.81.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, sell-side analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TYRA has been the subject of several analyst reports. Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.